TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Author:

Yeung David T.1234,Osborn Michael P.134,White Deborah L.345,Branford Susan2367,Braley Jodi2,Herschtal Alan8,Kornhauser Michael8,Issa Samar49,Hiwase Devendra K.134,Hertzberg Mark41011,Schwarer Anthony P.412,Filshie Robin413,Arthur Christopher K.414,Kwan Yiu Lam415,Trotman Judith41115,Forsyth Cecily J.416,Taper John41117,Ross David M.134,Beresford Jennifer8,Tam Constantine418,Mills Anthony K.419,Grigg Andrew P.420,Hughes Timothy P.1345

Affiliation:

1. Department of Haematology, and

2. Department of Genetics and Molecular Pathology and Centre for Cancer Biology, SA Pathology, Adelaide, Australia;

3. Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, Australia;

4. Australasian Leukemia and Lymphoma Group, Melbourne, Australia;

5. Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, Australia;

6. School of Molecular and Biomedical Science, and

7. School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia;

8. Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia;

9. Middlemore Hospital, Auckland, New Zealand;

10. Prince of Wales Hospital, Sydney, Australia;

11. School of Medicine, University of Sydney, Sydney, Australia;

12. Box Hill Hospital, Melbourne, Australia;

13. St. Vincent’s Hospital Melbourne, Melbourne, Australia;

14. Royal North Shore Hospital, Sydney, Australia;

15. Concord Hospital, Sydney, Australia;

16. Gosford Hospital, Gosford, Australia;

17. Nepean Hospital, Penrith, Australia;

18. Peter MacCallum Cancer Centre, Melbourne, Australia;

19. Princess Alexandra Hospital, Brisbane, Australia; and

20. Department of Clinical Haematology, Austin Hospital and University of Melbourne, Melbourne, Australia

Abstract

Key Points Using imatinib to treat CML first-line, with selective nilotinib switching, leads to excellent molecular response and survival. This strategy may be preferable to universal first-line use of more potent agents, considering efficacy, toxicity, and economic factors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3